Since sleep disturbances are intricately linked to metabolic dysregulation and cardiovascular dysfunction, studying the impact of SGLT2 inhibitors on sleep quality and OSA parameters in HF patients becomes pivotal. This evidence concerns the gene SLC5A2 and obstructive sleep apnea syndrome.